Absci

Alopecia
#Absci #Alopecia #Clinical trial

Absci reports positive data from Phase I alopecia trial 

Biopharmaceutical company Absci has reported positive data from the Phase I trial of its alopecia treatment.  ABS-201, an investigational anti-prolactin receptor (PRLR) antibody, was evaluated in a first-in-human, randomised, double-blind, placebo-controlled study in 32 healthy volunteers with and without androgenetic alopecia (AGA).  The medication proved to be well-tolerated across… Read More

#News

Therapeutic antibodies
#Absci #AI #AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Biologics #Generative AI #Machine learning

How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Machine learning: developing next generation antibody therapeutics’. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and… Read More

#Featured Podcasts #Podcasts

Antibodies
#Absci #Antibodies #Biologics #Biopharmaceuticals #Clinical trials

Absci becomes clinical-stage company with clinical trial initiation

Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More

#News

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Drug targets #Interview #Machine learning

New podcast: The continued evidence of AI’s drug discovery value

This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI’s drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can… Read More

#News

#Absci #Artificial intelligence (AI) #Collaboration #Generative AI #Oncology #The Memorial Sloan Kettering Cancer Center

Partners use generative AI to develop novel cancer therapeutics

The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More

#Cancer Research #News

#Absci #Antibodies #Artificial intelligence (AI) #Biologics #Generative AI #Interview

The next generation of AI

Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications.  Last year, a lot of focus was placed on artificial intelligence… Read More

#Exclusive Content

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Interview

How generative AI could improve drug discovery

Listen to this article on the DDW Podcast: Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI… Read More

#Exclusive Content

Tumour microenvironment
#Absci #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Oncology #St John’s Cancer Institute #Tumours

Partners use AI to speed up development of cancer therapies

AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies.   The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new… Read More

#Cancer Research #News